American Journal of Cardiology
Volume 102, Issue 4 , Pages 396-400 , 15 August 2008

Comparison of Increased Aspirin Dose Versus Combined Aspirin Plus Clopidogrel Therapy in Patients With Diabetes Mellitus and Coronary Heart Disease and Impaired Antiplatelet Response to Low-Dose Aspirin

Received 19 January 2008 ,Revised 24 March 2008 ,Accepted 24 March 2008.

References 

  1. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–1339
  2. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625–628
  3. Eikelboom JW, Hankey GJ, Thom J, Claxton A, Yi Q, Gilmore G, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost. 2005;3:2649–2655
  4. Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke. 2005;36:2289–2292
  5. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction randomised placebo-controlled trial. Lancet. 2005;366:1607–1621
  6. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation). N Engl J Med. 2001;345:494–502
  7. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  8. American Diabetes Association. Standards of medical care in diabetes (position statement). Diabetes Care. 2005;28(suppl):S4–S36
  9. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med. 2000;342:1040–1042
  10. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–2188
  11. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)—its relation to metabolic control. Thromb Res. 2004;113:101–113
  12. Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost. 2005;93:8–16
  13. Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin M, Unal A, et al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res. 2005;116:465–470
  14. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the Aspirin-Induced Platelet Effect (ASPECT) study. Diabetes. 2007;56:3014–3119
  15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  16. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218–1222
  17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430–2435
  18. Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the Plavix Use for Treatment of Diabetes (PLUTO-Diabetes) trial. Am Heart J. 2008;155(93):e1–e93e7
  19. Valles J, Santos MT, Aznar J, Velert M, Barbera G, Carmena R. Modulatory effect of erythrocytes on the platelet reactivity to collagen in IDDM patients. Diabetes. 1997;46:1047–1053
  20. Khosla PK, Seth V, Tiwari HK, Saraya AK. Effect of aspirin on platelet aggregation in diabetes mellitus. Diabetologia. 1982;23:104–107
  21. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717
  22. American Diabetes Association. Standards of medical care in diabetes—2008 (position statement). Diabetes Care. 2008;31(suppl):S12–S54
  23. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655
  24. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med. 2007;120:631–635
  25. Poulsen TS, Jorgensen B, Korsholm L, Bjorn Licht P, Haghfelt T, Mickley H. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res. 2007;119:555–562
  26. Hankey G, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606–617
  27. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78:1003–1007
  28. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156–3164
  29. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review. Eur J Vasc Endovasc Surg. 2004;27:456–465
  30. Cheng X, Chen WH, Simon DI. Aspirin resistance or variable response or both?. Am J Cardiol. 2006;98(suppl):11N–17N

PII: S0002-9149(08)00647-4

doi: 10.1016/j.amjcard.2008.03.074

American Journal of Cardiology
Volume 102, Issue 4 , Pages 396-400 , 15 August 2008

Article Tools

* Image Usage & Resolution